Drug Profile
SSR 482073
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in France
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 19 Dec 2002 Preclinical trials in CNS disorders in France (unspecified route)